Incannex Submits IND Application To The FDA For Dronabinol-Based Drug For Obstructive Sleep Apnea
Portfolio Pulse from Vuk Zdinjak
Incannex Healthcare Limited (NASDAQ:IXHL) has submitted an Investigational New Drug (IND) application to the US FDA for IHL-42X, a dronabinol-based drug for the treatment of obstructive sleep apnea. The IND includes comprehensive information on the safety, efficacy, development, manufacturing, and quality of IHL-42X. The clinical trial protocol for the IND opening clinical trial, a multi-site phase 2/3 clinical trial, is also detailed in the application.
July 21, 2023 | 2:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Incannex's submission of the IND application to the FDA for IHL-42X could potentially lead to the approval of the drug, which would be a significant milestone for the company. This could positively impact the company's stock in the short term.
The submission of the IND application is a crucial step in the drug approval process. If the FDA approves the application, it would allow Incannex to proceed with clinical trials, bringing the drug one step closer to market. This could potentially increase investor confidence in the company, leading to a positive impact on the stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100